Buchumschlag

Aspirin for secondary prevention of cardiovascular disease in 51 low-, middle-, and high-income countries

OBJECTIVE To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yoo, Sang Gune K. (VerfasserIn) , Chung, Grace S. (VerfasserIn) , Bahendeka, Silver K. (VerfasserIn) , Sibai, Abla M. (VerfasserIn) , Damasceno, Albertino (VerfasserIn) , Farzadfar, Farshad (VerfasserIn) , Rohloff, Peter (VerfasserIn) , Houehanou, Corine (VerfasserIn) , Norov, Bolormaa (VerfasserIn) , Karki, Khem B. (VerfasserIn) , Azangou-Khyavy, Mohammadreza (VerfasserIn) , Marcus, Maja E. (VerfasserIn) , Aryal, Krishna K. (VerfasserIn) , Brant, Luisa C. C. (VerfasserIn) , Theilmann, Michaela (VerfasserIn) , Cífková, Renata (VerfasserIn) , Lunet, Nuno (VerfasserIn) , Gurung, Mongal S. (VerfasserIn) , Mwangi, Joseph Kibachio (VerfasserIn) , Martins, Joao (VerfasserIn) , Haghshenas, Rosa (VerfasserIn) , Sturua, Lela (VerfasserIn) , Vollmer, Sebastian (VerfasserIn) , Bärnighausen, Till (VerfasserIn) , Atun, Rifat A. (VerfasserIn) , Sussman, Jeremy B. (VerfasserIn) , Singh, Kavita (VerfasserIn) , Saeedi Moghaddam, Sahar (VerfasserIn) , Guwatudde, David (VerfasserIn) , Geldsetzer, Pascal (VerfasserIn) , Manne-Goehler, Jennifer (VerfasserIn) , Huffman, Mark D. (VerfasserIn) , Davies, Justine I. (VerfasserIn) , Flood, David (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 22/29, 2023
In: The journal of the American Medical Association
Year: 2023, Jahrgang: 330, Heft: 8, Pages: 715-724
ISSN:1538-3598
DOI:10.1001/jama.2023.12905
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1001/jama.2023.12905
Verlag, kostenfrei, Volltext: https://jamanetwork.com/journals/jama/fullarticle/2808523
Volltext
Verfasserangaben:Sang Gune K. Yoo, MD, Grace S. Chung, PhD, Silver K. Bahendeka, MD, Abla M. Sibai, PhD, Albertino Damasceno, PhD, Farshad Farzadfar, MD, Peter Rohloff, MD, Corine Houehanou, MD, Bolormaa Norov, MSc, Khem B. Karki, MBBS, Mohammadreza Azangou-Khyavy, MD, Maja E. Marcus, PhD, Krishna K. Aryal, PhD, Luisa C.C. Brant, MD, Michaela Theilmann, MA, Renata Cífková, MD, Nuno Lunet, PhD, Mongal S. Gurung, PhD, Joseph Kibachio Mwangi, MD, Joao Martins, PhD, Rosa Haghshenas, BSc, Lela Sturua, PhD, Sebastian Vollmer, PhD, Till Bärnighausen, MD, Rifat Atun, MD, Jeremy B. Sussman, MD, Kavita Singh, PhD, Sahar Saeedi Moghaddam, MSc, David Guwatudde, PhD, Pascal Geldsetzer, ScD, Jennifer Manne-Goehler, MD, Mark D. Huffman, MD, Justine I. Davies, MD, David Flood, MD
Beschreibung
Zusammenfassung:OBJECTIVE To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. EXPOSURES Countries’ per capita income levels and world region; individuals’ socioeconomic demographics. MAIN OUTCOMES AND MEASURES Self-reported use of aspirin for secondary prevention of CVD. - RESULTS The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.2% [95% CI, 7.7%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middleincome countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. - CONCLUSION AND RELEVANCE Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.
Beschreibung:Gesehen am 14.12.2023
Beschreibung:Online Resource
ISSN:1538-3598
DOI:10.1001/jama.2023.12905

Ähnliche Einträge